C12Y 306/04005
Minus-end-directed kinesin atpase
Official title: Minus-end-directed kinesin ATPase (3.6.4.5)
C12Y306/04005 (Minus-end-directed kinesin atpase) appears on 3 US grants and 3 published applications in this corpus.
Search patents in C12Y- Granted patents
- 3
- Published applications
- 3
- Assignees
- 3
- Inventors
- 9
- Latest grant
- 15 Oct 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 1 |
| 2021 | 1 | 0 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 0 |
By publication year.
Recent patents
- Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C)15 Oct 2024US 12,116,574 B2Northwestern University
- Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C)14 Sep 2021US 11,118,180 B2Northwestern University
- Method of preventing transport of a neurotropic virus and identifying agents for achieving same11 Oct 2005US 6,953,661 B1The University of Sydney
- Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (klc1c)18 Aug 2022US 2022/0259591 A1Northwestern University
- Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (klc1c)11 Jun 2020US 2020/0181615 A1Northwestern University
- Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (klc1c)13 Jul 2017US 2017/0198290 A1Northwestern University
Most cited
By later US patents